University of Colorado Cancer Center leader Daniel LaBarbera, PhD, has received an innovation pilot grant from the cancer center’s Shared Resources program to develop complex 3D tissue and organoid models for high-throughput drug discovery and high-content imaging.
The Protocol Review and Monitoring System (PRMS) in the University of Colorado Cancer Center’s Clinical Trials Office is under new leadership.
Research Brain and Spinal Cancer
Among the biggest obstacles in studying and treating brain tumors are the blood-brain and blood-tumor barriers (BBTB). Generally, just a small amount of drug that is injected into the blood to treat brain tumors is able to penetrate blood vessel walls and accumulate in the brain.
An enzyme that has been identified as instrumental in the progression of many types of cancer is meeting its match in inhibitors synthesized and evaluated by University of Colorado (CU) Cancer Center researchers.
Research Brain and Spinal Cancer
Dmitri Simberg, PhD, an associate professor in the Department of Pharmaceutical Sciences in the Skaggs School of Pharmacy and a CU Cancer Center member, has released the results of a new study of the effectiveness of different types of fluorescent labels used to monitor the accumulation of liposomes in tumors.
Gripped
March 27, 2024
Just 18 months after his leukemia diagnosis and on the brink of a bone marrow transplant, Chen defied the odds with an inspiring ascent. Reflecting on his journey, Chen's resilience shines through as he remains optimistic and determined for the future.
EurekAlert
March 06, 2024
Researchers at the University of Colorado Anschutz Medical Campus found that drugs like botox may slow head and neck cancer progression by targeting nerve interactions in tumor environments, impacting immune responses. This study could lead to new treatments for patients intolerant to traditional therapies.
Mile High Magazine
February 25, 2024
Christopher Lieu, MD speaks on March being Colorectal Cancer Awareness Month and the importance of screening.
National Institutes of Health (NIH)
February 21, 2024
In 2024, the network will launch a pilot study, known as the Vanguard Study on Multi-Cancer Detection, to address the feasibility of using multi-cancer detection (MCD) tests in future randomized controlled trials.
Greg Glasgow
